Ipsen v. Conjupro & CSPC: Camptothecin Patent Case Consolidated in 56 Days
Ipsen Biopharm and Ipsen Biopharmaceuticals filed a second infringement action against Conjupro Biotherapeutics and CSPC Pharmaceutical Group over US12059497B2, covering stabilized camptothecin pharmaceutical compositions. Within 56 days of filing, the New Jersey District Court consolidated the action with a related earlier case — civil action 24-4991 — streamlining discovery and trial across all defendants.
Ipsen’s Second CSPC Action Folded Into Unified Patent Proceeding
On August 23, 2024, Ipsen Biopharmaceuticals, Inc. and Ipsen Biopharm Ltd. filed Civil Action No. 1:24-cv-08723 in the New Jersey District Court against Conjupro Biotherapeutics, Inc., CSPC Pharmaceutical Group Limited, and CSPC Ouyi Pharmaceutical Co., Ltd. The complaint asserted infringement of US Patent No. 12,059,497 B2, which covers stabilized camptothecin pharmaceutical compositions — a class of potent topoisomerase I inhibitor compounds with significant oncology applications. This case was filed approximately four months after Ipsen’s first action against the same defendants, Civil Action No. 24-4991, filed on April 15, 2024.
On October 18, 2024 — just 56 days after filing — the court entered an order consolidating civil actions 24-4991 and 24-8723 for all purposes, including discovery, case management, and trial. The consolidation was jointly requested by both sides. Case 24-8723 was administratively terminated by the clerk’s office, with all further filings directed to the 24-4991 docket. The defendants were given until November 4, 2024 to serve non-infringement and invalidity contentions specifically with respect to US12059497, and Ipsen until December 19, 2024 to serve infringement contentions in response.
The swift consolidation — agreed by both parties — suggests coordinated case management strategy rather than adversarial friction at this early stage. The inclusion of a separate schedule for US12059497 in the consolidation order signals that this patent entered the litigation later than those already subject to scheduling in 24-4991, and that the court treated it as a discrete but related dispute warranting integration. What remains unknown from the public record of 24-8723 is the precise scope of infringement alleged or whether any preliminary injunction posture has been adopted by Ipsen in the consolidated proceeding.
Filing to Case Consolidated in 56 days
56 days from filing to consolidation — well below median time-to-resolution for NJ patent cases
What case consolidation means: proceedings unified under 24-4991
Consolidation terminates 24-8723 administratively, not on merits
Administrative consolidation under Federal Rule of Civil Procedure 42(a) allows a court to combine cases sharing common questions of law or fact. Here, the court ordered that 24-8723 be administratively terminated — meaning the case did not end on the merits. All claims, patents, and parties from 24-8723 survive and proceed under the 24-4991 docket. No rights are extinguished; the termination is purely procedural and docket-management driven.
Procedural consolidationIpsen retains all patent claims in a unified forum
For Ipsen, consolidation concentrates its enforcement strategy across both actions into a single proceeding. All discovery, claim construction, and trial preparation will now address both the earlier patents in 24-4991 and US12059497 together. This typically benefits the patent holder by reducing duplicative effort and enabling a coherent claim narrative across related patents — though it also means Ipsen must manage a broader patent portfolio simultaneously in one proceeding.
Plaintiff advantage: unified enforcementCSPC and Conjupro face consolidated multi-patent defence
Conjupro and CSPC’s agreement to consolidation suggests they see strategic efficiency in a single proceeding. However, consolidation exposes them to simultaneous invalidity and non-infringement challenges across multiple patents, increasing litigation burden. The extended content deadline for US12059497 — to November 4, 2024 — indicates the defendants negotiated additional preparation time for the newer patent, consistent with standard practice when a second action is absorbed mid-schedule.
Multi-patent defence riskCamptothecin IP dispute signals competitive tension in oncology formulations
Camptothecin-based drugs — including irinotecan and topotecan derivatives — represent a significant segment of oncology therapeutics. Patent disputes over stabilized formulation technology suggest that follow-on manufacturers are developing competing compositions, likely in anticipation of market entry. The consolidation of multiple actions against CSPC, a major Chinese pharmaceutical group, is consistent with originator companies defending formulation IP against generics or biosimilar-adjacent entrants with global manufacturing scale.
Oncology formulation IP battlegroundFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Ipsen | Individual | Biopharmaceutical group — holder of US12059497B2 covering stabilized camptothecin compositionsSearch in Eureka ↗ |
| Co-Plaintiff | IPSEN BIOPHARM LTD. | Company | Search in Eureka ↗ |
| Defendant | CONJUPRO BIOTHERAPEUTICS, INC. | Company | Conjupro Biotherapeutics and CSPC Pharmaceutical entities — Chinese pharmaceutical group and US affiliateSearch in Eureka ↗ |
| Co-Defendant | CSPC PHARMACEUTICAL GROUP LIMITED | Company | Search in Eureka ↗ |
| Co-Defendant | CSPC Ouyi Pharmaceutical Co., Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for IpsenSearch in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for IpsenSearch in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for IpsenSearch in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for IpsenSearch in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing IpsenSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The October 18, 2024 consolidation order is a procedural instrument, not a merits determination. The court’s language — ‘consolidated for all purposes, including discovery, case management, and trial’ — signals full integration of 24-8723 into 24-4991, with US12059497 treated as a discrete patent requiring its own contentions schedule. Neither party conceded infringement or validity. The separate November 4 and December 19 deadlines for US12059497 contentions indicate the court recognized this patent’s later entry into the litigation and accommodated it without disrupting the broader schedule.
US12059497B2 — Stabilized Camptothecin Pharmaceutical Compositions
US Patent No. 12,059,497 B2, filed under application number US17/208042, covers stabilizing camptothecin pharmaceutical compositions. Camptothecin and its derivatives — including irinotecan and topotecan — are potent topoisomerase I inhibitors used extensively in colorectal, lung, and ovarian cancer treatment. Formulation stability is a significant technical challenge for this drug class, as camptothecin compounds undergo pH-dependent lactone ring opening that reduces therapeutic activity. Patent protection over stabilized formulations therefore represents a commercially critical innovation layer beyond the active compound itself.
For the pharmaceutical sector, formulation patents on established oncology compounds like camptothecin derivatives represent a key secondary exclusivity strategy. US12059497B2 suggests Ipsen has secured protection over specific stabilization technology, potentially covering excipient combinations, pH control methods, or packaging systems that maintain lactone form integrity. Any competitor — including generic or specialty pharma entrants — developing camptothecin-based injectable or oral formulations for the US market should assess claim scope carefully. CSPC’s involvement signals this patent is commercially relevant to products in active development or approaching regulatory submission.
Should you run an FTO against US12059497B2?
Any company developing stabilized camptothecin pharmaceutical compositions — including irinotecan liposomes, topotecan formulations, or novel camptothecin analogue drug products — intended for the US market should treat US12059497B2 as a live FTO risk. The fact that Ipsen has already enforced this patent within months of its issuance, and has done so against a major multinational pharmaceutical group, signals aggressive enforcement intent. R&D teams working on oncology formulation platforms, particularly those involving stabilization of lactone-ring-containing compounds, should assess whether their formulation choices fall within the claim scope of this patent before advancing to IND or NDA filing.
PatSnap Eureka’s FTO Search Agent allows IP teams to map the claims of US12059497B2 against their own formulation technology, identify prior art that may inform invalidity arguments, and monitor Ipsen’s broader camptothecin patent family for continuation filings. Eureka can also surface related litigation and IPR proceedings to give in-house counsel a complete picture of the patent’s enforcement history and vulnerability — enabling faster, more defensible FTO opinions before your product enters the US market.
Run a freedom-to-operate analysis on US12059497B2 to assess your product’s exposure
Run FTO in Eureka →Similar Camptothecin Formulation Patent Cases in NJ District Court
Cases involving oncology formulation patents enforced in the New Jersey District Court, including stabilized camptothecin and topoisomerase inhibitor composition disputes.
What this case signals for the oncology pharmaceutical IP landscape
Ipsen’s dual-action strategy against CSPC and Conjupro reveals how originator pharma companies are enforcing formulation patents in the NJ District Court.
Multi-patent, multi-action enforcement is a deliberate originator strategy
Ipsen filed two separate actions — four months apart — covering different patents against the same defendants. This staggered filing approach, followed by consolidation, is consistent with originator companies securing additional patents on incremental innovations and deploying them sequentially. Companies developing camptothecin formulations should map Ipsen’s full portfolio early to anticipate downstream filings.
NJ District Court consolidation timelines are fast — 56 days in this case
The New Jersey District Court processed this consolidation within 56 days of filing. For defendants and plaintiffs alike, this signals that the court is actively managing its patent docket for efficiency. Parties filing related actions in NJ should be prepared for rapid procedural orders and tightly controlled scheduling, particularly under Local Patent Rules.
Ipsen v CONJUPRO — key questions answered
Case 1:24-cv-08723 was an infringement action filed by Ipsen Biopharm and Ipsen Biopharmaceuticals against Conjupro Biotherapeutics and CSPC Pharmaceutical entities on August 23, 2024 in the New Jersey District Court over US12059497B2. On October 18, 2024 — 56 days after filing — the court consolidated it with related case 24-4991 and administratively terminated 24-8723. All proceedings continue under 24-4991.
US12059497B2 covers stabilizing camptothecin pharmaceutical compositions. Camptothecin derivatives such as irinotecan and topotecan are topoisomerase I inhibitors used in oncology. The patent protects formulation technology addressing the stability challenges inherent to the camptothecin lactone ring, which is pH-sensitive and tends toward inactive open-ring forms in solution. Application number is US17/208042.
Both cases involved the same defendants — Conjupro Biotherapeutics, CSPC Pharmaceutical Group, and CSPC Ouyi — and related Ipsen patents. Consolidation was jointly requested by the parties and ordered by the court to unify discovery, case management, and trial. This avoids duplicative proceedings and conflicting rulings. The consolidation is procedural and does not reflect a merits determination on either side.
The defendants named across the consolidated proceedings are Conjupro Biotherapeutics, Inc. (a US entity), CSPC Pharmaceutical Group Limited (a major Chinese pharmaceutical conglomerate), and CSPC Ouyi Pharmaceutical Co., Ltd. (a CSPC subsidiary). Ipsen’s actions against all three parties are now consolidated and proceeding under case 1:24-cv-4991 in the New Jersey District Court.
New Jersey Local Patent Rules govern the exchange of infringement and invalidity contentions on a structured schedule. In the consolidation order, the court set specific deadlines under L. Pat. R. 3.6(c)-(f) and 3.6(g)-(i) for US12059497 — giving defendants until November 4, 2024 for invalidity contentions and Ipsen until December 19, 2024 for infringement contentions. These rules impose disciplined early disclosure obligations that shape how each party frames its legal theories.
PatSnap Eureka searches patents and litigation data to answer instantly.